Literature DB >> 9377129

Developmental pattern of fetal growth hormone, insulin-like growth factor I, growth hormone binding protein and insulin-like growth factor binding protein-3.

P Pirazzoli1, E Cacciari, R De Iasio, M C Pittalis, P Dallacasa, S Zucchini, S Gualandi, S Salardi, C David, S Boschi.   

Abstract

AIMS: To evaluate the developmental pattern of fetal growth hormone (GH), insulin-like growth factor I (IGF-I), GH binding protein (GHBP) and IGF binding protein-3 (IGF-3); to determine the implications for fetal growth.
METHODS: Serum GH, IGF-I, GHBP and IGFBP-3 were measured in 53 fetuses, 41 aged 20-26 weeks (group A) and 12 aged 31-38 weeks (group B). Fetal blood samples were obtained by direct puncture of the umbilical vein in utero. Fetal blood samples were taken to rule out beta thalassaemia, chromosome alterations, mother to fetus transmissible infections, and for maternal rhesus factor. GHBP was determined by gel filtration chromatography of serum incubated overnight with 125I-GH. GH, IGF-I and IGFBP-3 were determined by radioimmunoassay.
RESULTS: Fetal serum GH concentrations in group A (median 29 micrograms/l, range 11-92) were significantly higher (P < 0.01) than those of group B (median 16.7 micrograms/l, range 4.5-29). IGF-I in group A (median 20 micrograms/l, range 4.1-53.3) was significantly lower (P < 0.01) than in group B (median 75.2 micrograms/l, range 27.8-122.3). Similarly, IGFBP-3 concentrations in group A (median 950 micrograms/l, range 580-1260) were significantly lower than those of group B (median 1920 micrograms/l, range 1070-1770). There was no significant difference between GHBP values in group A (median 8.6%, range 6.6-12.6) and group B (median 8.3%, range 6-14.3). Gestational age correlated positively with IGF-I concentrations (P < 0.0001) and IGFBP-3 (P < 0.0001) and negatively with GH (P < 0.0001). GHBP values did not correlate with gestational age. Multiple regression analysis showed a negative correlation between GH:IGF-I ratio and fetal growth indices
CONCLUSIONS: The simultaneous evaluation of fetal GH, IGF-I, IGFBP-3 and GHBP suggests that the GH-IGF-I axis might already be functional in utero. The progressive improvement in the efficiency of this axis in the last part of gestation does not seem to be due to an increase in GH receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377129      PMCID: PMC1720686          DOI: 10.1136/fn.77.2.f100

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  35 in total

1.  Concepts relating the pituitary growth hormone to somatic growth of the normal child.

Authors:  H P SECKEL
Journal:  AMA J Dis Child       Date:  1960-03

2.  A new funipuncture technique: two-needle ultrasound- and needle biopsy-guided procedure.

Authors:  L Bovicelli; L F Orsini; P A Grannum; M C Pittalis; C Toffoli; B Dolcini
Journal:  Obstet Gynecol       Date:  1989-03       Impact factor: 7.661

3.  Effect of maternal fasting on fetal growth, serum insulin-like growth factors (IGFs), and tissue IGF messenger ribonucleic acids.

Authors:  M L Davenport; A J D'Ercole; L E Underwood
Journal:  Endocrinology       Date:  1990-04       Impact factor: 4.736

4.  The interrelationship of growth hormone (GH), liver membrane GH receptor, serum GH-binding protein activity, and insulin-like growth factor I in the male rat.

Authors:  T Bick; T Amit; R J Barkey; P Hertz; M B Youdim; Z Hochberg
Journal:  Endocrinology       Date:  1990-04       Impact factor: 4.736

5.  Somatotrophin in antenatal and perinatal growth and development.

Authors:  Z Laron; A Pertzelan
Journal:  Lancet       Date:  1969-03-29       Impact factor: 79.321

6.  Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study.

Authors:  F P Hadlock; R B Harrist; R S Sharman; R L Deter; S K Park
Journal:  Am J Obstet Gynecol       Date:  1985-02-01       Impact factor: 8.661

7.  Regulation of growth hormone (GH) secretion by GH-releasing factor, somatostatin, and insulin-like growth factor I in ovine fetal and neonatal pituitary cells in vitro.

Authors:  B L Silverman; M Bettendorf; S L Kaplan; M M Grumbach; W L Miller
Journal:  Endocrinology       Date:  1989-01       Impact factor: 4.736

8.  Serum growth hormone binding protein activity in healthy neonates, children and young adults: correlation with age, height and weight.

Authors:  A Silbergeld; L Lazar; B Erster; R Keret; R Tepper; Z Laron
Journal:  Clin Endocrinol (Oxf)       Date:  1989-09       Impact factor: 3.478

9.  Infancy growth pattern related to growth hormone deficiency.

Authors:  J Karlberg; K Albertsson-Wikland
Journal:  Acta Paediatr Scand       Date:  1988-05

10.  Isolated human growth hormone deficiency due to the hGH-I gene deletion with (type IA) and without (the Israeli-type) hGH antibody formation during hGH therapy.

Authors:  Y Nishi; H Masuda; S Nishimura; M Kihara; S Suwa; K Tachibana; M Takeda; Y Okada; I Matsuda
Journal:  Acta Endocrinol (Copenh)       Date:  1990-02
View more
  3 in total

1.  Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth.

Authors:  Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 2.  Metabolic-endocrine disruption due to preterm birth impacts growth, body composition, and neonatal outcome.

Authors:  Lea Sophie Möllers; Efrah I Yousuf; Constanze Hamatschek; Katherine M Morrison; Michael Hermanussen; Christoph Fusch; Niels Rochow
Journal:  Pediatr Res       Date:  2021-05-26       Impact factor: 3.953

3.  Early nutrition and weight gain in preterm newborns and the risk of retinopathy of prematurity.

Authors:  Deborah K VanderVeen; Camilia R Martin; Reshma Mehendale; Elizabeth N Allred; Olaf Dammann; Alan Leviton
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.